Control of disease attributable to Haemophilus influenzae type b and the National Immunization Program

Pediatrics

Volumn 110, Issue 4, 2002, Pages 820-823

  Cody Meissner, H ^a,c   Pickering, Larry K ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DIS CONTR AND PREV   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HIB IMUNE; TRIHBIT; VIRULENCE FACTOR;

BACTERIAL COLONIZATION; BACTERIAL INFECTION; COST BENEFIT ANALYSIS; COST CONTROL; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INTUSSUSCEPTION; MENINGITIS; NOTE; PHARYNX; PNEUMONIA; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; INFANT; MASS IMMUNIZATION; NATIONAL HEALTH PROGRAMS; OUTCOME ASSESSMENT (HEALTH CARE); PROGRAM EVALUATION; UNITED STATES; VACCINES, CONJUGATE;

EID: 0036792180     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.110.4.820     Document Type: Note

References (26)

1. Broome CV. Epidemiology of H influenzae type b in the United States. Pediatr Infect Dis J. 1987;6:779-782
2. Centers for Disease Control and Prevention. Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children-United States, 1998-2000. MMWR Morb Mortal Wkly Rep. 2002; 51:234-237
3. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med. 2001;344:564-572
4. Zhou F, Bisgard KM, Yusuf HR, Deuson RR, Bath SK, Murphy TV. Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis. Pediatrics. 2002;110:653-661
5. Abramson JS, Pickering LK. US immunization policy. JAMA. 2002;287: 505-509
6. American Academy of Pediatrics. Haemophilus influenzae infections. In: Pickering LK, ed. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2000:262-272
7. Petersen GM, Silimeri DR, Rotter JI, et al. Genetic factors in H influenzae type b disease susceptibility and antibody acquisition. J Pediatr. 1987; 110:229-233
8. Takala AK, Mourman O, Kleemoia M, et al. Preceding respiratory infection predisposing for primary and secondary invasive Haemophilus influenzae type b disease. Pediatr Infect Dis J. 1993;12:189-195
9. Anderson P, Smith DH, Ingram DL, Wilkins J. Wehrle PF, Howie VM. Antibody of polyribophate of H influenzae type b in infants and children: effect of immunization with polyribophosphate. J Infect Dis. 1977; 136(suppl):S57-S62
10. Ada G. Vaccines and vaccination. N Engl J Med. 2001;345:1042-1053
11. Heath PT. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J. 1998;17(suppl):S117-SI22
12. Schlessinger Y, Granoff DM. Avidity and bactericidal activity of antibody elicited by different H influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA. 1992;267:1489-1494
13. Amir J, Scott MG, Nahm MG, et al. Bactericidal and opsonic activity of IgG1 and IgG2 anti-capsular antibodies to H influenzae type b. J Infect Dis. 1990;162:163-171
14. Murphy TV, Pastor P, Medley F, et al. Decreased Haemophilus colonization in children vaccinated with H influenzae type b conjugate vaccine. J Pediatr. 1993;122:517-523
15. Centers for Disease Control and Prevention. Haemophilus b conjugate vaccines for prevention of H influenzae type b disease among infants and children two months of age and older. MMWR Morb Mortal Wkly Rep. 1991;40:1-7
16. Heath PT, Booy R, Azzopardi HJ, et al. Non-type b Haemophilus influenzae disease: clinical and epidemiologic characteristics in the H influenzae type b vaccine era. Pediatr Infect Dis J. 2001;20:300-305
17. Urwin G, Krohn JA, Deaver-Robinson K, Wenger JD, Farley MM. Invasive disease due to Haemophilus influenzae serotype f: clinical and epidemiologic characteristics in the H influenzae serotype b vaccine era. The Haemophilus influenzae Study Group. Clin Infect Dis. 1996;22:1069-1076
18. Adderson EE, Byington CL, Spencer L, et al. Invasive serotype a Haemophilus influenzae with a virulence genotype resembling H influenzae type b: emerging pathogen in the vaccine era? Pediatrics. 2001; 108(1). Available at: URL: http://www.pediatrics.org/cgi/content/full/108/ 1/e18
19. Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of H influenzae type b. J Infect Dis. 1983;147:1100-1106
20. Goldblatt D, Johnson M, Evans J. Antibody responses to H influenzae type b conjugate vaccine in sickle cell disease. Arch Dis Child. 1996;75: 159-161
21. Webber SA, Sandor GG, Patterson ME, et al. Immunogenicity of H influenzae type b conjugate vaccine in children with congenital asplenia. J Infect Dis. 1993;167:1210-1212
22. Guinan EC, Molrine DC, Antin JH, et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation. 1994;57:677-684
23. Heath PT, Booy R, Griffiths H, et al. Clinical and immunological risk factors associated with H influenzae type b conjugate vaccine failure in childhood. Clin Infect Dis. 2000;319:73-80
24. Breukels MA, Spanjaard L, Sanders LAM, Rijkers GTR, Immunological characterization of conjugated H influenzae type b vaccine failure in infants. Clin Infect Dis. 2001;32:1700-1705
25. Meissner C, Reimer CB, Black C, et al. Interpretation of IgG subclass values: a comparison of two assays. J Pediatr. 1990;117:726-731
26. Brukels MA, Zijde EMJ, van Tol MJD, Rijkers GT. Concentration and avidity of anti-H. influenzae type b antibodies in serum samples obtained from patients for whom vaccination failed. Clin Infect Dis. 2002; 34:191-197